COA

CJC-1295 / IPAMORELIN nothing more. nothing less.

Ipamorelin / CJC-1295 (No DAC) is a dual-peptide research blend combining a selective GHS-R1a agonist with a GHRH analog. Studied in research involving synergistic GH release and endocrine pathway modeling.

Purity >99.93%Form Lyophilized PowderNo Endotoxins

Ships Tomorrow

Order within

10MG $85.00
Pharmacy $255.99 Save 67%
>99.93% Purity
cGMP-Compliant
SAME DAY SHIPPING
US MADE
Quantity Price Per Unit
5 – 9
10+

For research use only — not for human consumption, therapeutic, or diagnostic use. By adding to cart you acknowledge these terms.

Blank. Credentials

Institutional-grade credentials you can verify

Double Validation HPLC + MS
Priority Delivery Fast Shipping
Expert Support US-Based Team
Risk-Free 14-Day Guarantee
Volume Savings Tiered Pricing

About This Compound

Deep technical insights for clinical research

Primary Research Applications

This compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.

Synergistic Growth Hormone Stimulation

Combines GHSR agonism with GHRH stimulation for enhanced and prolonged GH pulse generation through complementary mechanisms.

GH Axis Optimization

Stacks dual-pathway GH axis stimulation to maximize pulsatile release without desensitization of either receptor system.

Research Community Feedback

"Consistency is paramount in our cellular model testing. Blank's peptides have maintained the tightest purity specs of any RUO vendor we've audited."

Dr. Julian Kessler

Lead Investigator, Biomatrix Labs

"The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification. Professional grade synthesis."

Anika S. Singh

Synthetics Quality Control

"Finally, a supplier that doesn't hide behind consumer marketing. Stark, clear, and high-purity. Exactly what a modern lab needs."

Prof. David Emmerich

Applied Peptide Research

Complete The Protocol

Pairs & Supplies

The compounds and tools researchers stack with CJC-1295 / IPAMORELIN.

AOD-9604

AOD-9604

$65.00
Add to Cart
TESAMORELIN

TESAMORELIN

$95.00
Add to Cart
BACTERIOSTATIC WATER

BACTERIOSTATIC WATER

$10.00
Add to Cart

Peer-Reviewed Literature

Related Studies

Ipamorelin · 1998

Ipamorelin, the First Selective Growth Hormone Secretagogue

European Journal of Endocrinology

Foundational paper establishing ipamorelin as a selective GHS-R1a agonist. Unlike GHRP-2 and GHRP-6, ipamorelin does not stimulate ACTH or cortisol, making it uniquely selective.

Ipamorelin · 1999

Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers

Pharmaceutical Research

Dose-escalation trial demonstrated ipamorelin produces a GH release episode peaking at 0.67 hours with terminal half-life of 2 hours across five dose levels in healthy male volunteers.

Ipamorelin · 1999

Ipamorelin Induces Longitudinal Bone Growth in Rats

Growth Hormone & IGF Research

Ipamorelin dose-dependently increased longitudinal bone growth rate from 42 to 52 µm/day with pronounced dose-dependent effects on body weight gain in adult female rats.

CJC-1295 · 2006

Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in Healthy Adults

Journal of Clinical Endocrinology & Metabolism

Single injection of CJC-1295 produced dose-dependent GH increases of 2–10 fold sustained for 6+ days and IGF-I elevations of 1.5–3 fold for 9–11 days, with half-life of 5.8–8.1 days.

CJC-1295 · 2007

Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295

Journal of Clinical Endocrinology & Metabolism

CJC-1295 increased trough and mean GH secretion and IGF-I production while preserving physiological GH pulsatility — distinguishing it from continuous GH replacement.

CJC-1295 · 2009

Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Profile Changes in Normal Adult Subjects

Growth Hormone & IGF Research

Proteomic analysis of sera from 11 healthy men demonstrated significant protein profile changes reflecting GH/IGF-1 axis activation one week after CJC-1295 injection.

From the Lab

Related Blog Posts